Aquis Stock Exchange Weekly Highlights 01/07/24
0
Published:
July 1, 2024
Most recent
One Health Group plc announced its audited results for the year ended 31 March 2024.
Financial Highlights
• Turnover of £23.3m (2023: £20.5m) an increase of 14%.
• Underlying operating profit £1.62m (2023: £1.53m) an increase of 6%.
• Cash at bank at year end of £4.7m (2022: £3.3m) an increase of 42%.
• Final dividend proposed of 4.07p per share, in line with the Board's stated dividend policy.
• Total dividend paid in respect of the financial year of 6.10p per share, with dividend cover of 1.8 times.
Operational Highlights
• 13% increase in new NHS patient referrals to 13,266, a new record.
• 6,169 surgical procedures undertaken, an increase of 7% on last year.
• 13% expansion in outpatient capacity taking the total number of outreach clinics to 35.
• Attracted 22 new Surgical Consultants to the business to support growth, making a total of 63.
• Secured new 5-year contracts with the two largest commissioners from April 2024.
Read more…
Financial Highlights
• Turnover of £23.3m (2023: £20.5m) an increase of 14%.
• Underlying operating profit £1.62m (2023: £1.53m) an increase of 6%.
• Cash at bank at year end of £4.7m (2022: £3.3m) an increase of 42%.
• Final dividend proposed of 4.07p per share, in line with the Board's stated dividend policy.
• Total dividend paid in respect of the financial year of 6.10p per share, with dividend cover of 1.8 times.
Operational Highlights
• 13% increase in new NHS patient referrals to 13,266, a new record.
• 6,169 surgical procedures undertaken, an increase of 7% on last year.
• 13% expansion in outpatient capacity taking the total number of outreach clinics to 35.
• Attracted 22 new Surgical Consultants to the business to support growth, making a total of 63.
• Secured new 5-year contracts with the two largest commissioners from April 2024.
Read more…
Time To ACT plc announced that its GreenSpur business has received an award of €705,000 (circa £613,000) from the BEETHOVEN Project, an initiative for the sustainable development of advanced magnetic materials for energy solutions. The award, which will be spread over four years, provides GreenSpur with income which will be used to support the development of a fully characterised, high powered Rare Earth-free magnet for use in several industrial applications. Read more…
EDX Medical Group plc announced today it has signed an exclusive distribution agreement with Curesponse Ltd, to market the cResponse™ cancer assay in the UK, Sweden, Finland, Norway and Denmark. The Company states that cResponse™ is a groundbreaking platform that biologically assesses how an individual patient's living tumour tissue responds to selected medicines, identifying the most effective treatment options. It is the only clinical-grade technology providing biological response data for chemotherapy, targeted biologics, and immunotherapy drugs. This platform helps clinicians rapidly pinpoint optimal treatments, potentially saving lives, reducing treatment costs, and accelerating the discovery and development cycles for pharmaceutical companies seeking new cancer drugs. Read more…
Ananda Developments PLC announced the results from recent preclinical studies investigating the efficacy of MRX1 (Patent Pending) in treating cardiac fibrosis and heart failure with preserved ejection fraction (HFpEF).
Highlights:
• Administration of MRX1 has shown significant cardioprotective effects in a mouse study, demonstrating its potential as a treatment for patients with heart failure with preserved ejection fraction (HFpEF).
• The research involved detailed assessments of cardiac function, plasma CBD levels, and molecular markers of heart failure, fibrosis, and inflammation.
• MRX1 exhibited multiple traits which indicate an effectiveness in mitigating cardiac fibrosis and improving heart health.
• This data has been included in Ananda's International Patent Application for MRX1.
• The successful outcomes suggest MRX1 could be a valuable therapeutic option for HFpEF and other cardiac conditions and the Company says it is currently investigating next steps on how to bring this promising treatment to clinical use.
Read more…
Highlights:
• Administration of MRX1 has shown significant cardioprotective effects in a mouse study, demonstrating its potential as a treatment for patients with heart failure with preserved ejection fraction (HFpEF).
• The research involved detailed assessments of cardiac function, plasma CBD levels, and molecular markers of heart failure, fibrosis, and inflammation.
• MRX1 exhibited multiple traits which indicate an effectiveness in mitigating cardiac fibrosis and improving heart health.
• This data has been included in Ananda's International Patent Application for MRX1.
• The successful outcomes suggest MRX1 could be a valuable therapeutic option for HFpEF and other cardiac conditions and the Company says it is currently investigating next steps on how to bring this promising treatment to clinical use.
Read more…
Invinity Energy Systems plc announced its Full Year Results for the year ended 31 December 2023. It confirmed that these are in line with expectations.
Highlights
• 511% increase in total income YoY to £22.0m (2022: £3.6m).
• 136.7 MWh of Invinity batteries sold or awarded funding during 2023 for delivery in 2024 or 2025.
• 170% increase in total global pipeline of commercial interest to 6.6 GWh as of 17 June 2024 (24 May 2023: 2.47 GWh).
• Debt-free with £53.2m of cash at 31 May 2024 (2023: £15.4m) reflecting a post period £57.4m fundraise cornerstoned by a £25m investment from UK Infrastructure Bank completed in May 2024.
Read more…
Highlights
• 511% increase in total income YoY to £22.0m (2022: £3.6m).
• 136.7 MWh of Invinity batteries sold or awarded funding during 2023 for delivery in 2024 or 2025.
• 170% increase in total global pipeline of commercial interest to 6.6 GWh as of 17 June 2024 (24 May 2023: 2.47 GWh).
• Debt-free with £53.2m of cash at 31 May 2024 (2023: £15.4m) reflecting a post period £57.4m fundraise cornerstoned by a £25m investment from UK Infrastructure Bank completed in May 2024.
Read more…
OTAQ PLC announced a placing has been conducted by Dowgate Capital to issue £1.7 million 10% Convertible Loan Notes 2027 at par, with a potential further issue by OTAQ of up to £1.0 million further Convertible Loan Notes 2027 under a Broker Option granted by the Company to Dowgate Capital. Read more…
